Maravai LifeSciences Holdings, Inc.
MRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.05 | 1.70 | -0.34 |
| FCF Yield | -2.95% | 7.02% | 27.57% | 7.35% |
| EV / EBITDA | -9.46 | 2.36 | 5.80 | 15.67 |
| Quality | ||||
| ROIC | -24.24% | 0.50% | 23.39% | 26.73% |
| Gross Margin | 41.79% | 48.52% | 80.87% | 82.41% |
| Cash Conversion Ratio | -0.03 | -1.06 | 1.09 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.54% | -28.76% | 45.94% | 77.41% |
| Free Cash Flow Growth | -136.58% | -88.31% | 46.69% | 179.01% |
| Safety | ||||
| Net Debt / EBITDA | -0.35 | 0.05 | -0.08 | 0.04 |
| Interest Coverage | -4.94 | -0.69 | 28.13 | 18.33 |
| Efficiency | ||||
| Inventory Turnover | 3.01 | 2.89 | 3.92 | 2.73 |
| Cash Conversion Cycle | 146.48 | 170.19 | 140.97 | 166.37 |